This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Tevra's antitrust claims will fail at trial, Bayer tells US court in trial brief

( July 17, 2024, 20:04 GMT | Official Statement) -- MLex Summary: Bayer Healthcare argued in a trial brief that Tevra's claims that it illegally attempted to inhibit sales of generic topical imidacloprid products from 2017-20 would fail at trial. Bayer noted that during that time, it offered certain pet specialty retailers and distributors a discount it they would carry Bayer's imidacloprid product exclusively. Bayer said Tevra's "far-fetched claim faces numerous legal hurdles," including proof of market power. Tevra must also establish substantial foreclosure, Bayer said, arguing that it offered its incentives to only a small fraction of distribution and only a small discount in exchange for exclusivity. Jury selection for the trial is expected to begin July 19 before US District Judge Beth Labson Freeman of the Northern District of California. See court filing. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections